Articles Vol. 64 No. 2 15/03/2023

15. EVALUATING THE SAFETY OF MEASLE VACCINE (MVVAC) MANUFACTURED BY POLYVAC THROUGH PHARMACOVIGILANCE ACTIVITIES

Le Thu Nga1,2, Nguyen Thuy Huong1,2, Nguyen Dang Hien1,2, Le Thi Hoa1,2, Tran Minh Nguyet1,2
1 Center for research and production of vaccines and biologicals, Hanoi
2 Trung tâm Nghiên cứu, Sản xuất Vắc xin và Sinh phẩm Y tế, Hà Nội
Corresponding author: lethunga1801@gmail.com
DOI: 10.52163/yhc.v64i2.617
11 Views
18 Downloads
Keywords
Measles vaccine, MVVAC, pharmacovigilance, adverse events after vaccination.
Abstract

Objective: To evaluate the safety of the measles vaccine MVVAC produced by POLYVAC through
pharmacovigilance activity. A post-vaccination adverse event is an abnormality of health, including injection site or systemic manifestations occurring after vaccination, not necessarily attributable to the use of the vaccine, including common post-vaccination reactions and serious post-vaccination adverse events The most common adverse events following administration of measles vaccine produced by POLYVAC are usually local symptoms such as itching, pain, swelling or redness or both swelling and redness at the injection site; systemic symptoms such as fever below 39°C and other symptoms (malaise, fatigue, loss of appetite).
Subjects and methods: Collection and analysis of post-vaccination adverse events recorded from
batches of measles vaccine MVVAC produced by POLYVAC and used in immunization in 2019-
2021. From there, evaluate the safety of this vaccine.
Results: The measles vaccine MVVAC produced by POLYVAC and used from 2019 to 2021
had the following adverse event rates: fever ≤39 °C with a rate of 0.004%; swelling, redness at the
injection site has a rate of 0.014% and other symptoms have a rate of 0.0016%.
Conclusion: The measles vaccine MVVAC produced by POLYVAC and used from 2019 to 2021
meets the requirements for post-injection safety.

References
[1]
Đặng Thị Thanh Huyền, Dương Thị Hồng, “Một Google Scholar
[2]
số đặc điểm dịch tễ học và lâm sàng của bệnh sởi Google Scholar
[3]
tại Việt Nam năm 2013-2014”, Tạp chí Y học dự Google Scholar
[4]
phòng, 2016, tập 26, số 4 (177), tr.98-106. Google Scholar
[5]
Bộ Y tế, “Hướng dẫn quốc gia về cảnh giác Google Scholar
[6]
Dược”, 2021. Google Scholar
[7]
Đoàn Huy Hậu, Đào Xuân Vinh, Đinh Hồng Google Scholar
[8]
Dương và CS, “Đánh giá tính an toàn và tính sinh Google Scholar
[9]
miễn dịch của vắc xin sởi MVVAC do POLYVAC Google Scholar
[10]
sản xuất từ chủng AIK-C trên người tình nguyện Google Scholar
[11]
(giai đoạn 1 và 3)”, Tạp chí Y học dự phòng, Google Scholar
[12]
, tập XXI, số 4, tr. 110-117. Google Scholar